AptamiR successfully completed three rounds of Angels Financing and a Series A, raising a total of $7,000,000.

AptamiR is now seeking to raise tranches of a $15-20M Series B financing while concurrently evaluating geographic licensing opportunities and strategic partnerships.

1. Upcoming AptamiR Milestones for Metabolic Indications:

Activities during the next 3 years:

Pre- Clinical Activities:

  • Selection of Generation 2.5 Oligonucleotide Therapeutic (ONTs) Molecules targeting miRNA-22 and miRNA-515 in primary cultures of human adipocytes
    • Efficacy studies in mouse models of DIO, T2DM and NAFLD/NASH
    • Acute and chronic toxicology studies in mice and monkeys

Regulatory Activities:

  • Submission of pre-IND and IND dossiers

Clinical Activities:

  • Phase 1 Clinical studies of antagomirs and agomirs in cohorts of  patients with obesity, diabesity and/or MAFLD

2. Upcoming AptamiR Milestones for Ovarian Cancer Indications:

Year 1: Targets identification in silico and validation in vitro in human cell lines.

Year 2: Drug Candidates Efficacy Studies in vivo in patient-derived tumor xenograft (PDX) mouse models of Ovarian Cancer

Year 3: Toxicology Studies of Lead Candidates

Year 4: Initiation of Clinical Studies